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Stem cell transplantation can be associated with signiﬁcant periods of thrombocytopenia, necessitating
platelet transfusions and contributing to the risk of bleeding. Thrombopoietin receptor agonists have been
shown to enhance platelet counts in other clinical settings, and so a phase 1 clinical trial was conducted to
assess the safety, pharmacokinetics, and maximum tolerated dose of once-daily eltrombopag in patients
undergoing stem cell transplantation with conditioning regimens containing total body irradiation 400 cGy.
Eltrombopag was examined at dosage levels of 75, 150, 225, and 300 mg given orally once daily for 27 days,
starting at 24 to 48 hours post-transplantation. Pharmacokinetic sampling was performed over a 24-hour
period after the ﬁrst dose of eltrombopag, as well as during the second week of treatment (steady-state).
Nineteen patients were enrolled, 15 of whom completed protocol treatments. Three patients completed each
dose level up to 225 mg, and 6 completed treatment at the highest dose of 300 mg. Four patients were
replaced because drug compliance was <75% of planned doses. No dose-limiting toxicities were observed in
this heterogeneous post-transplantation patient population. Common adverse events were related to stan-
dard stem cell transplantation. One episode of pulmonary embolus occurred 9 days after discontinuation of
eltrombopag, and the only other thromboembolic episode was a grade 2 catheter-related clot. We conclude
that up to 27 days of once-daily dosing of eltrombopag after stem cell transplantation is well tolerated.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Patients undergoing stem cell transplantation experience
signiﬁcant thrombocytopenia, often related to effects of the
preparative regimen, which usually consists of high-dose
chemotherapy or a combination of chemotherapy and total
body irradiation (TBI). This period of thrombocytopenia
increases the risk for bleeding and necessitates platelet
transfusions [1].
Many patients do not respond well to platelet trans-
fusions, even though storage and processing methods have
improved signiﬁcantly in recent years. The short survival of
platelets in vivo also contributes to a frequent requirement
for signiﬁcant transfusion support before platelet engraft-
ment, criteria for which have been deﬁned by the Center for
International Bone Marrow Transplantation Research
(CIBMTR) [2].
In a retrospective analysis of our center’s platelet trans-
fusion use and time to platelet engraftment, we found that
amean of 5.3 (median, 3) platelet transfusions were required
during the ﬁrst 30 days post-transplantation (range, 0 to 57
days), and that the median time to platelet engraftmentdgments on page 1751.
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13.10.002was 17 days for recipients of an autologous stem cell trans-
plant and 19 days for recipients of an unrelated donor
transplant [3].
The development of thrombopoietic agents for treating
thrombocytopenia has evolved signiﬁcantly in recent years.
Recombinant human thrombopoietin (TPO) and its pegy-
lated derivatives once held promise as clinically useful
agents [4,5]. However, these agents were associated with
episodes of persistent thrombocytopenia owing to the
development of autoantibodies that neutralized endogenous
TPO [6,7]. Other agents considered for the clinical treatment
of thrombocytopenia included interleukins, such as IL-3, IL-6,
and IL-11 [8].
Second-generation TPO agonists with unique pharmaco-
logic properties have been developed and Food and Drug
Administrationeapproved since 2008 [9]. Eltrombopag,
a nonpeptide TPO receptor agonist, is approved as an oral
agent for the treatment of chronic idiopathic thrombocyto-
penia purpura (ITP), as well as thrombocytopenia associated
with chronic hepatitis C [10-13]. Drug-related adverse events
(AEs) in patients with ITP, such as headache, nasopharyngitis,
nausea, and fatigue, are of low-grade severity [11,12].
Eltrombopag has been examined for thrombopoietic effects
in other settings, including phase II studies in patients with
solid tumors receiving carboplatin/paclitaxel [14], in patients
with myelodysplastic syndrome and acute myelogenous
leukemia (AML) [15], and in patients with severe aplastic
anemia [16].Transplantation. Published by Elsevier Inc. All rights reserved.
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be desirable in the post-transplantation period, there is
rationale for examining TPOmimetics in this setting. There is
also an interest in mitigating the radiation damage to bone
marrow in the event of nuclear terror events [17]. Thus, we
focused this phase I dose escalation study on patients
receiving TBI as part of conditioning for stem cell trans-
plantation, to examine the safety of eltrombopag in the post-
transplantation setting.
METHODS
Study Design
This phase I open-label dose-escalation clinical trial, approved by the
Research Subjects Review Board of the University of Rochester, was con-
ducted to evaluate the safety and pharmacokinetics of eltrombopag
administered at 4 different dose levels: 75, 150, 225, and 300 mg given once
daily for 27 days starting at 24 to 48 hours after stem cell infusion. This dose
range was selected based on doses previously found to be effective in
treating chronic ITP, [11,12] which was the only approved indication at the
time the protocol for this study was planned [10].
The daily maximum allowed dose in the ITP population is 75 mg.
Ongoing clinical trials of eltrombopag in patients withmyeloid malignancies
had administered doses as high as 300 mg. In stem cell transplant recipients
who underwent TBI, it was anticipated that higher doses of eltrombopag
might be required in states with decreased megakaryocyte mass from
radiation injury to bonemarrowwith or without bonemarrow toxicity from
preconditioning chemotherapy. Thus, our clinical study design tested
a dosage range of 75 to 300 mg/day.
The study drug was started at 24 hours in most cases, but in some cases
was delayed up to 48 hours to accommodate pharmacokinetic studies. A
course of 27 days was chosen because in a retrospective study of time to
platelet engraftment, >95% of comparable transplant recipients had
engrafted by this time [3]. A complete blood count with differential and
serum creatinine and serum liver enzyme levels were obtained pre-TBI,
post-TBI, and either twice weekly or weekly thereafter until platelet
engraftment. Blood samples were collected for serum TPO measurements
pre-TBI, post-TBI, and before stem cell infusion, and then at weeks 1 and 4
after stem cell infusion. The primary objectives of the study were to
establish safety and to deﬁne a maximum tolerated dose (MTD).
Inclusion/Exclusion Criteria
Eligibility requirements included age 18 years and Karnofsky perfor-
mance status 70% in patients undergoing standard of care stem cell
transplantation for any disease with a conditioning regimen containing
planned administration of 400 cGy TBI. Graft source could be from an
autologous, related sibling, or unrelated donor. Because the goal of the study
was safety determination in the setting of TBI and stem cell rescue, it was
decided to include both autologous and allogeneic transplant recipients,
given that they both experience signiﬁcant periods of thrombocytopenia and
many overlapping toxicities. Cord blood graft recipients were not included.
Patients with active infection, those with renal or hepatic dysfunction, and
those at risk for thromboembolism based on known genetic thrombophilias
or history of thromboembolic disease in the previous 6 months were
excluded. Granulocyte colony-stimulating factor could be administered post-
transplantation in accordance with usual clinical practice.
Dose Escalation
Dose escalation was based on a standard 3 þ 3 design. A group of 3
patients were enrolled at a given dose level; if none of these patients
experienced dose-limiting toxicity (DLT), then the dose could be escalated. If
1 of the 3 patients experienced DLT, then 3 more patients would be enrolled
at the same dose level. If no additional patients experienced a DLT, then dose
escalation could occur, but if 2 or more of the 6 patients experienced a DLT,
then that dose would be the MTD. Dose deescalation to 50mg/day or 25mg/
day was provided for in the event that the 75-mg/day dose proved too toxic;
however, this deescalation was not required, because of the successful dose
escalation through the 4 dosing levels.
For patients who achieved a platelet count of 200,000 to 400,000/mL
during the 27 days of eltrombopag administration, a dose reduction of
25 mg per day was instituted. If the platelet count rose to>400,000/mL, then
eltrombopag was discontinued until the platelet count fell to 150,000/mL.
Dose adjustments for Asian patients were speciﬁed because of known
higher exposures [18], but no patients of Asian origin were accrued to the
present study.
At the completion of each dose level, a review of all AEs and serious
adverse events (SAEs) was conducted before any patient was enrolled at thenext dose level. This study was conducted under the purview of the Data
Safety Monitoring Committee of the University of Rochester. Six patients
were planned in the last cohort for additional safety evaluation. Patients
who were unable to take at least 75% of the planned doses were replaced to
allow adequate evaluation of safety.
Determination of AEs and DLT
All AEs and SAEs were recorded and assessed for association with the
study drug. AEs were graded based on Common Terminology Criteria for
Adverse Events version 3.0. An AE was deﬁned as any untoward medical
occurrence in a patient temporally associated with the use of eltrombopag
whether or not considered related to its use.
An SAEwas deﬁned in accordancewith standard criteria as an event that
resulted in death, was life-threatening, required hospitalization or prolon-
gation of hospitalization, resulted in disability or incapacity, or resulted in
a congenital anomaly or birth defect. DLT was deﬁned by protocol as a grade
3 or higher AE determined to be probably or deﬁnitely related to the study
drug. The MTD was deﬁned as the highest dose (300 mg) if no DLT was
observed, or the highest dose at which less than one-third of the patients
experienced toxicities not expected in the standard TBI/stem cell trans-
plantation setting.
Pharmacokinetics
Pharmacokinetic samples were obtained before and at 1, 2, 4, 6, 8 and
24 hours after the ﬁrst dose of eltrombopag, as well as during the second
week of treatment (ie, pharmacokinetic steady-state). Plasma samples were
analyzed for eltrombopag by GlaxoSmithKline using a validated analytical
method [19]. Plasma pharmacokinetic parameters were determined using
standard noncompartmental methods, and dose proportionality (ie, how
plasma exposure increases in proportion to increases in dose administered)
was assessed by a power model using log-log transformed data (Phoenix
WinNonlin 6.0; Pharsight, Mountain View, CA).
Platelet Engraftment
Platelet engraftment was as deﬁned by the CIBMTR as the ﬁrst of
3 consecutive days of a platelet count 20,000/mL without platelet trans-
fusions for 7 days and/or the ﬁrst day of a platelet count 100,000/mL
without platelet transfusions for 7 days [2]. Guidelines for transfusion
support stipulated a 10,000/mL threshold for platelets in the absence of
bleeding and a hemoglobin concentration of 8.0 g/dL for RBC transfusion in
the absence of other symptoms. The time to platelet engraftment and the
number of platelet transfusions required by day 30 and day 100 post-
transplantation were recorded for all enrolled patients.
Serum Thrombopoietin Levels
Serum was collected at indicated times for the analysis of TPO levels by
ELISA (R&D Systems, Minneapolis, MN). Assays were performed in accor-
dance with the manufacturer’s instructions, with a lower limit of detection
of 7.4 pg/mL.
Statistical Methods
Implementation of the 3 þ 3 dose escalation design resulted in enroll-
ment of 16 evaluable patients. The median time to engraftment was
computed using a Kaplan-Meier estimate of the time to engraftment. Serum
TPO levels were compared across time points using a 2-way mixed ANOVA
model as well as random intercepts to describe the between-subject vari-
ation. TPO levels were log-transformed to correct for skewness, and 1 was
added to each value because of the presence of 0s (undetectable levels).
RESULTS
Patient Demographics
The study was open over a 2-year period. Thirty-six
patients were offered the study, and 15 declined participa-
tion. Of the 21 patients who consented to participate, 19 were
enrolled and 2 were screen failures (1 because of active
infection and 1 because of delayed administration of condi-
tioning). Table 1 presents demographic data for the 19
enrolled study patients. One patient self-identiﬁed as
Hispanic, 1 patient self-identiﬁed as African-American, and
17 patients self-identiﬁed as Caucasian.
Table 1 also presents information on underlying diseases
for which transplantation was performed, conditioning regi-
mens, TBI doses, donor types, and graft types. Seven patients
received 1200 cGy TBI, all of whom underwent conditioning
Table 1
Patient Characteristics
Characteristic Value
Race/ethnicity
White/Hispanic/black, n 18/1/1
Sex, n (%)
Male 7 (37)
Female 12 (63)
Age, yr, median (range) 52 (20-69)
Disease, n (%)
AML 7 (37)
Acute lymphoblastic leukemia 3 (16)
Lymphoma 4 (21)
Other* 5 (26)
TBI dose, n
400 cGy 5
600 cGy 7
1200 cGy 7
Conditioning regimen, n
TBI/cyclophosphamide 7
TBI þ ﬂudarabine/pentostatin  extracorporeal
photopheresis
12
Methotrexate for GVHD prevention, n (%) 6 (31)
Peripheral blood stem cell graft, n (%) 18 (95)
Donor type, n
Autologous 1
Matched sibling 6
Matched unrelated 12
* Includes myelodysplastic syndrome, myeloﬁbrosis, chronic myeloge-
nous leukemia, and chronic lymphocytic leukemia.
Table 2
Drug Compliance
ID Drug
Dose,
mg
Donor
Type/ TBI
Dose, cGy
Methotrexate
GVHD
Prophylaxis
Drug
Compliance,
% (no. days)
Reason for
Noncompliance
01 75 URD/600 No 100 (27) NA
02 75 Sibling/
1200
No 100 (27) NA
04 75 URD/600 No 100 (27) NA
06 150 Autologous/
1200
NA 100 (20)* NA
07 150 URD/600 No 96 (26) NA
08 150 Sibling/600 No 93 (25) NA
09 225 URD/400 No 100 (14)* NA
10 225 URD/400 No 93 (25) NA
11 225 URD/600 No 30 (8) Patient withdrew;
unrelated acute
kidney failure
12 225 URD/400 No 100 (27) NA
13 300 URD/1200 No 33 (9) Unrelated
respiratory failure
14 300 Sibling/
1200
No 100 (27) NA
15 300 URD/1200 Yes 89 (24) NA
16 300 Sibling/
1200
Yes 11 (3) Patient withdrew;
refused to
swallow pills
17 300 URD/600 Yes 44 (12) Patient withdrew
18 300 Sibling/
1200
No 96 (26) NA
19 300 Sibling/400 Yes 100 (27) NA
20 300 URD/400 Yes 96 (26) NA
21 300 URD/600 Yes 100 (27) NA
URD indicates matched unrelated donor; sibling, matched sibling donor;
NA, not applicable.
* Patient 9 had 100% compliance despite only 14 days of daily eltrom-
bopag. This was because eltrombopag was withheld for a platelet count
>400,000/mL according to the predeﬁned rules for dose reduction. Patient
6 was able to stop at day 20 due to a platelet count >400,000/mL after 20
days.
J.L. Liesveld et al. / Biol Blood Marrow Transplant 19 (2013) 1745e1752 1747with TBI/cyclophosphamide (2 doses of 60 mg/kg). Seven
patients received reduced-intensity conditioning with 600
cGy TBI, and 5 patients received 400 cGy with a conditioning
regimen containing ﬂudarabine or pentostatin and with or
without extracorporeal photopheresis [20].
Study Drug Compliance
Table 2 summarizes the drug compliance of enrolled
patients. Four patients (nos. 11, 13, 16, and 17) were not
eligible for safety assessment because they received <75% of
the 27 planned daily doses of eltrombopag. Thus, an addi-
tional patient was enrolled at the given dose level to replace
each of these patients. In only 1 case was discontinuation
related to unwillingness to swallow the pills. In this post-
transplantation population with an expected prevalence of
mucositis, no patients withdrew for that reason. Thirteen
patients (68%) had mucositis at a maximum of grade 1, and 5
patients (26%) had grade 3 mucositis. Only 5 patients
required dose reduction or a temporary hold of eltrombopag
owing to a platelet count 200,000/mL during the 27 days of
administration.
AEs
Nineteen patients completed the investigational drug
administration period and were followed for AEs at least
30 days past the last dose of the drug. No DLTs were
observed at any of the 4 dosing levels (3 patients at 75 mg,
3 at 150 mg, 4 at 225 mg, and 9 at 300 mg). One patient
received 8 doses before deciding to withdraw from the
study. One patient received 9 doses before intubation for
acute respiratory distress syndrome from a respiratory
syncytial viruseinduced pneumonitis. One patient with-
drew after 3 days of dosing because of unwillingness to
swallow the pills, and another patient withdrew after 12
days of dosing for personal preference (no mucositis or
other cause speciﬁed).Eltrombopag was generally well tolerated in this patient
population. The majority of the AEs experienced were
deemed related to the stem cell transplantation process. At
the 225-mg dose level, 2 patients experienced renal toxicity,
but this was attributed to tacrolimus therapy. In 1 of these
patients, the renal toxicity resolved and did not recur after
the tacrolimus was held and the dose reduced and eltrom-
bopag was restarted. Supplemental Table 1 lists all of the AEs
experienced by all of the patients enrolled who received at
least 1 dose of eltrombopag.
Most of the toxicities were grade 1 and were encountered
in the course of stem cell transplantation. One grade 2
catheter-related thrombosis occurred during thrombocyto-
penia. No AEs were deemed likely or deﬁnitely related to the
investigational drug, and none led to withdrawal of a patient
from the study. Twelve patients (63%) had a grade 1 alanine
aminotransferase elevation, and 5 patients (26%) had a grade
2 elevation, but no grade 3 or 4 elevations were noted.
Table 3 lists grade 3 and 4 AEs occurring in this study pop-
ulation at a rate >10%.SAEs
Eight patients experienced a total of 12 SAEs (Table 4).
One case of pulmonary embolism was considered possibly
related to eltrombopag therapy. This patient had a diagnosis
of AML secondary to treatment for breast cancer with
a chromosome 11q abnormality. She was in the 75-mg dose
cohort.
Table 3
Noncytopenia Grade 3 and 4 AEs Occurring in >10% of Subjects (n ¼ 19)
Body System/AE %
Cardiac
Hypertension 10.5
Constitutional
Fatigue 10.5
Gastrointestinal
Dehydration 10.5
Diarrhea 16
Dysphagia 16
Mucositis 26
Nausea 32
Infection
Fever 32
Infection with normal absolute neutrophil count 10.5
BK viruria 10.5
CMV reactivation 21
Lymphatics
Edema 15.8
Metabolic
Hyperglycemia 47
Hypertriglyceridemia 10.5
Hypocalcemia 10.5
Hypomagnesemia 10.5
Hypokalemia 26
Hypophosphatemia 15.8
Neurologic
Syncope 10.5
Pain
GI/oral cavity 15.8
Headache 21
Pulmonary
Dyspnea 15.8
Hiccoughs 10.5
Renal
Renal failure 15.8
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had a platelet count of 226,000/mL. In accordance with
protocol, the eltrombopag dose was decreased to 50 mg/day.
On the last day of eltrombopag adminstration (day 27), her
platelet count was 241,000/mL. The pulmonary embolus
occurred 9 days after discontinuation of eltrombopag, at
which time her platelet count was 252,000/mL. A computed
tomography scan obtained at the time of the event showed
a subsegmental defect in the right lung.
The patient had other known risk factors for thrombosis,
including decreased ambulation during a recent previous
hospitalization for urosepsis. She had received dalteparin
prophylaxis during all hospital admissions, and she was
never hypoxemic. The embolus occurred at home afterTable 4
SAEs
ID Body
System
SAE
01 Infection Urosepsis
01 Vascular Pulmonary embolism
04 Infection Cytomegalovirus infection with fever
04 Infection Clostridium difﬁcile infection with nausea and diar
11 Renal Acute renal failure
11 GI GVHD of the gut (initially reported as severe diarr
12 Renal Acute renal failure
12 GI Gastroparesis
13 Pulmonary/
respiratory
Acute respiratory distress syndrome (initially repo
as respiratory failure)
14 Cardiac Pericarditis
15 Renal Acute renal failure
16 Dermatologic GVHD skin rashthe discontinuation of deep vein thrombosis prophylaxis.
Bilateral lower extremity ultrasound showed no deep vein
thromboses, and a central venous catheter remained intact
without associated thrombus.
Renal toxicity was observed in the 2 patients at the
225-mg dose level andwas associatedwith tacrolimus. There
was 1 case of acute renal failure in a patient receiving
300 mg/day who required dialysis after receiving 89%
(24 days) of the scheduled doses. This event was deemed
unlikely related to use of the study drug, given the presence
of multiple other potential etiologies for renal failure,
including tacrolimus, BK virus reactivation at day þ5, and
morbid obesity with underlying diabetes mellitus. This
patient was receiving tacrolimus and several other nephro-
toxic medications and had received cidofovir for BK virus
reactivation. Magnetic reaonance imaging of the kidneys was
compatible with acute tubular necrosis, and there was no
evidence of renal vein thrombosis.
Nine of the 19 patients who received 1 or more doses of
eltrombopag had expired at the time of this report. All of the
deaths were related to complications from transplantation.
The causes of death and days of death post-transplantation
were cytomegalovirus (CMV) pneumonitis on day þ104;
fungal infection on day þ328; GVHD on days þ39, þ134,
and þ195; acute respiratory distress syndrome from respi-
ratory syncytial virus pneumonitis on day þ38; and disease
relapse on days þ117, þ192, and þ211. The remaining
10 patients were alive without disease relapse (range of
survival, 425 to 1065 days).Platelet Engraftment Times and Number of Platelet
Transfusions
The median time to platelet engraftment for all
patients on this study who completed at least 75% of the
planned doses was 16 days (range, 0 to 86 days)
(Figure 1A). Three patients did not demonstrate a platelet
count nadir (<20,000/mL). The median number of platelet
transfusions up to the day of engraftment was 4 units
(range, 0 to 68 units) for all evaluable patients. Only 1
patient required more than 7 transfusions up to the day of
engraftment (Figure 1B); this was the patient who became
dialysis-dependent at the 300-mg dose. This patient had
received 1200 cGy TBI and 1.5  108 mononuclear cells/kg
from an unrelated marrow donor. On day þ5, the patient
developed hematuria with a positive PCR for BK viruria
and was treated with cidofovir. Neutrophil engraftment
was noted at day þ22, but platelet engraftment did notRelated Unexpected Outcome
No No Resolved
Possibly No Resolved
No No Resolved
rhea No No Improved and resolved
Unlikely No Resolved
hea) Unlikely No Resolved
Unlikely No Resolved
Unlikely No Continuing at time of death
rted Unlikely No Death
Unlikely Yes Resolved
Unlikely No Continuing (sequelae)
Unlikely No Resolved
Figure 1. Time to platelet engraftment according to the CIBMTR deﬁnition for each patient (A) and number of platelet transfusions required up to day 100 (B). Bar
shading distinguishes distinct dosing cohorts as deﬁned in the brackets.
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>150,000/uL. The time to platelet engraftment was also
complicated by CMV reactivation, renal failure, onset
of GVHD, return of a baseline chromosomal marker in
marrow indicating minimal residual disease, and other
medication exposures.
Granulocyte colony-stimulating factor was routinely
given to patients post-transplantation, and with the excep-
tion of the patient with delayed platelet engraftment
described above, all patients demonstrated the expected
recovery of granulocytes. Thirteen of the 19 enrolled patients
underwent follow-up bone marrow biopsy analysis between
approximately 30 days and 60 days post-transplantation. All
but 3 had normal cellularity and normal megakaryocytes. All
3 of the patients who developed hypocellularity had trili-
neage hypocellularity. One patient had evidence of recurrent
AML, and 1 patient with myeloﬁbrosis still had grade 2þ
ﬁbrosis at that early time point. Seventeen of the 19 patients
lived to day þ100, and all but 4 (1 with relapsed disease, 2
with CMV reactivation, and the aforementioned patient with
delayed platelet engraftment) had a platelet count >40,000/mL. Eight patients had a platelet count >100,000/mL (range,
118,000 to 279,000/mL).
Pharmacokinetics of Eltrombopag
Eltrombopag was initiated as a once-daily dose on dayþ1
orþ2 after stem cell infusion. Summary plasma eltrombopag
concentration time proﬁles are shown in Figure 2, and the
pharmacokinetic parameters are summarized in Table 5.
Dose-dependent increases in plasma eltrombopag exposure
were observed for both the ﬁrst dose and the steady-state
dose during week 2, although exposure at the 300-mg dose
level was slightly lower than expected. Dose-proportionality
assessment showed that increases in maximum concentra-
tion and area under the curve were slightly lower than dose-
proportional; that is, the increase in plasma exposure to
eltrombopag was less than the proportional increase in dose
(Table 5).
Serum Thrombopoietin Levels
Serumwas assayed for TPO concentration on 4 occasions;
pre-TBI, post-TBI, after 1 week of eltrombopag exposure, and
Figure 2. Mean  SEM plasma eltrombopag concentration by dose level after single-dose administration (A, ﬁrst dose) and at steady state (B, dose during week 2).
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time point are shown in Figure 3. Mean levels did not change
signiﬁcantly throughout the course of transplantation or
after exposure to eltrombopag (P ¼ .31). Levels were higher
after 1 week of exposure; however, the difference did not
reach statistical signiﬁcance, possibly owing to the wide
variation among patients.
DISCUSSION
Although high-grade bleeding episodes are rare in stem
cell transplantation recipients [21], they are mitigated
against by prophylactic use of platelet transfusions, typically
given when the platelet count drops to <10,000/mL. Platelet
transfusions are generally effective in this setting, but their
effects are short-lived because of processing considerations,
short storage times, and a short half-life after transfusion.
Furthermore, platelet transfusions can be associated with
febrile or allergic reactions, transfusion related lung injury,
refractoriness, immune modulation, and, rarely, infectious
agent transmission [22]. Thus, a strategy for diminishing the
need for platelet transfusions would be desirable in the post-
transplantation setting.
This phase I dose-escalation study has demonstrated that
eltrombopag can be safely administered to patients under-
going stem cell transplantation when started at 24 to 48
hours after stem cell infusion and continued for up to 27 days.
The majority of patients were able to ingest this oral medi-
cation throughout the post-transplantation period, with only
1 patient withdrawing because of an inability to swallow
pills. In this population of patients who often experience
mucositis related to effects of the conditioning regimen, asTable 5
Summary of Pharmacokinetic Parameters by Dose Level after Single-dose Adminis
Dose, mg n tmax, h, Median (range) Cmax
Single Dose Steady State Sing
75 3 4.07 (4.00-6.00) 4.00 (2.08-6.33) 4.57
150 3 2.08 (2.00-4.25) 2.00 (1.00-4.00) 8.02
225 3 4.00 (2.25-4.32) 2.00 (1.92-4.08) 18.7
300 9 4.00 (2.42-23.93) 5.97 (2.00-6.50)* 13.5
Dose- proportionalityy NA NA 0.81
NA indicates not applicable; tmax, time to maximum level; Cmax, maximum concen
* n ¼ 7.
y Slope (95% conﬁdence interval) from power model analysis; a value of 1 woulwell as to the effects of low-dose methotrexate used in GVHD
prophylaxis, there was a concern about their ability to ingest
this agent, but all of the evaluable patients were able to
complete at least 25 of the 27 days of the planned course of
eltrombopag administration.
Overall, increases in plasma eltrombopag exposure were
slightly less than the proportional increases in dose, driven
largely by the lower-than-expected plasma exposure at the
300-mg dose level. This may be a result of incomplete
absorption or saturation of enteral-oral absorption capacity.
Pharmacokinetic data suggest that plasma exposure of
eltrombopag in this population was generally similar to that
observed in previous studies of healthy patients and patients
with solid tumors [23,24]; however, those studies did not
evaluate doses >200 mg.
The most common adverse reactions reported in the ITP
clinical studies that were more frequent in patients receiving
eltrombopag compared with those in the placebo arm were
nausea, diarrhea, vomiting, increased liver transaminase
levels, myalgia, oropharyngeal pain, and pharyngitis [10]. In
this phase I study, the incidence of side effects was no greater
than that expected in the post-transplantation setting.
Although 3 of our patients experienced renal events (2 renal
toxicity and 1 acute renal failure), the incidence of renal
events in the study (15.8%) did not exceed that typically seen
in transplantation recipients (25% to 50%) [25]. Our patients
will be followed for late effects such as cataract formation for
up to 2 years after enrollment. Cataracts were observed in
toxicology studies of eltrombopag in rodents [18]. Because all
of our study patients received TBI and some received corti-
costeroids, most would have had other predisposing factorstration and at Steady State
, mg/mL, Geometric Mean (CV%) AUC (0 - s), mg$h/mL, Geometric
Mean (CV%)
le Dose Steady State Single Dose Steady State
(13) 9.23 (37) 48.9 (21) 123 (24)
(35) 15.6 (28) 88.6 (18) 253 (19)
(66) 25.2 (65) 190 (55) 340 (76)
(67) 22.3 (62)* 146 (66) 378 (60)*
(0.28-1.35) 0.66 (0.16-1.15) 0.81 (0.31-1.31) 0.80 (0.23-1.28)
tration; CV, coefﬁcient of variation; AUC, area under the curve.
d be dose-proportional.
Figure 3. The mean  SEM serum TPO levels as measured by ELISA at the
indicated time points (n ¼ 15 to 16). None of these levels was signiﬁcantly
different from baseline as assessed by a 2-way mixed ANOVA model.
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who receive TBI develop cataracts within 10 years [26]. The 2
patients who underwent transplantation for myeloﬁbrosis
demonstrated eventual normalization of marrow reticulin
staining, 1 patient at 3 months and the other at 1 year.
Clinical trials examining the efﬁcacy and safety of both
eltrombopag and romiplostim have reported a 2% to 4% rate
of thrombosis [16]. In our study, 1 patient experienced
catheter-related thrombosis, and 1 patient had a pulmonary
embolus at 9 days after discontinuation of eltrombopag, at
a platelet count of 252,000/mL. Because of the presence of
other risks of thrombosis at the time, the pulmonary
embolism event was considered possibly related to eltrom-
bopag, but was not deemed a DLT. Appropriate dose reduc-
tions were built into the protocol for platelet count
elevations in this phase I study. In future examinations of this
agent in the post-transplantation period, observation for any
increased thrombotic events and/or early discontinuation of
eltrombopag in cases of elevated platelet counts and possibly
decreasing the course of therapy to less than 27 days to avoid
counts >100,000/mL may be desirable. Although there is
some evidence suggesting that platelet counts fall after
discontinuation of eltrombopag in patients with ITP, we
found no signiﬁcant decline in platelet counts in the post-
transplantation setting after cessation of eltrombopag in
the absence of other post-transplantation complications or
disease relapse.
TPO acts on multilineage progenitors, and eltrombopag is
expected to do so as well. A phase II study of patients with
aplastic anemia refractory to immunosuppression found that
after 12 weeks of once-daily administration of 50 to 150 mg
eltrombopag, 44% of patients with aplastic anemia had
a hematologic response in at least 1 lineage [15]. Improve-
ments in myeloid cell, lymphoid cell, and RBC lineages were
also noted, with no increase in marrow ﬁbrosis. Others,
including our own group [27], have reported that eltrom-
bopag and other small-molecule TPO mimetics [28] enhance
human umbilical cord blood hematopoietic progenitors
in vivo and in vitro and promote multilineage hematopoiesis
through the expansion of hematopoietic stem/progenitor
cells in vivo in xenograft models. These observations suggest
that future trials of eltrombopag in the post-transplantation
setting will require examination of the effects on all hema-
topoietic lineages as well as attention to immunemodulatory
effects as related to engraftment and GVHD, considering that
lymphoid progenitors may be affected as well.Although the effects of eltrombopag on relapse cannot be
assessed in a phase I study, there had been a concern about
the possible stimulation of leukemia cell proliferation from
the expression of c-Mpl by leukemia blast cells. Thus far,
there has been no evidence that eltrombopag stimulates
leukemia blasts or progenitor cells, and there is in fact
evidence sugesting that it actually may be suppressive to
such cells [29,30]. Eltrombopag may induce myeloid dif-
ferentiation mediated by a reduction in intracellular iron
levels [31]. Larger comparative studies are needed to assess
the effect of eltrombopag on relapse after stem cell
transplantation.
In ITP- and chronic hepatitis Ceassociated thrombocyto-
penia (the 2 currently approved indications for eltrombo-
pag), megakaryocyte mass is normal to increased. In stem
cell transplantation recipients, this would not be the case
after chemotherapy and TBI, and so we measured TPO levels
at various times after TBI and after eltrombopag exposure in
our series of patients. As has been noted in other disease
states with low/absent megakaryocyte mass, such as aplastic
anemia [15], serum thrombopoetin levels did not change
signiﬁcantly after eltrombopag exposure.
Because cord blood allografts are associated with pro-
longed engraftment times, agents such as eltrombopag
might have the greatest clinical impact in those transplants
compared with transplants with other graft sources [32,33].
In this study, time to platelet engraftment and number of
platelet transfusions required compared favorably with that
seen in a retrospective analysis of transplants at our center
[3], but an assessment of efﬁcacy is not possible in this small
phase I population with heterogeneous donor sources, graft
types, and conditioning regimens. Eltrombopag also could
have a potential role in settings of delayed engraftment or
with viral-mediated or medication-mediated thrombocyto-
penia after stem cell transplantation [34].
In this study, oral eltrombopag was well-tolerated when
started at 24 to 48 hours after stem cell transplantation and
continued for up to 27 days. Although the MTD was not
reached at the highest dose level of 300 mg, the lack of
proportional increases in pharmacokinetic parameters from
225 mg to 300 mg suggests some saturation effects beyond
the 225-mg daily dosing. Considering that the ultimate use of
eltrombopag in the stem cell transplantation population will
be a form of supportive care, doses reaching plasma satura-
tion level should sufﬁce without pushing doses to levels that
may cause clinical toxicities. Higher-phase studies are
needed to conﬁrm the safety data and to determine the
impact on platelet engraftment, need for platelet trans-
fusions, bleeding and thrombotic risks, cost-beneﬁt analysis,
and other outcome measures in the post-transplantation
setting.
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